Jie Xu, Ph.D.

Education

• Vrije Universiteit Brussel, PhD (2006 Sep – 2010 Jun);

• Harbin Medical University, Bachelor and Master (1998 Sep – 2007 Jul)

Work experience

• Fudan University, Institutes of Biomedical Sciences (2019 Aug – now);

• Shanghai Jiao Tong University, School of Medicine (2012 Jan – 2019 Jul);

• Flanders Institutes of Biotechnology, Belgium (2010 Jul – 2011 Dec)

• Shanghai Tenth People’s Hospital, Tongji University (2005 Aug – 2006 Aug)

Contact

Institutes of Biomedical Sciences, Fudan University, Shanghai 200032 Tel: +86

Email: jie_xu@fudan.edu.cn

Lab homepage:

Biography

Jie Xu received the Bachelor’s and Master’s degrees in clinical medicine from Harbin Medical University in 2005, and then worked for one year as a surgeon in a hospital affiliated to Tongji University. His strong interest in translational research encouraged him to study in Vrije Universiteit Brussel and to obtain a doctoral degree in Bioscience Engineering. After his postdoctoral training in Flanders Institutes of Biotechnology in Belgium, he returned to China to start his research as an independent researcher in translational oncology. In 2019, Jie Joined Fudan University to continue his exciting research in cancer immunotherapy.

Research Areas

• Translational Oncology;

• Cancer immunotherapy;

• Drug development and pharmacology

Research interest

Dr. Jie Xu’s study focuses on translational oncology and oncoimmunotherapy. His research group is especially interested in discovering new mechanisms in cancer immune evasion, leading to the development of first-in-class therapeutic antibodies under preclinical/clinical development. He is associate editors of Frontiers in Immunology, Frontiers in Pharmacology, and BMC Cancer. Dr. Xu was selected for an Excellent Young Scholar Award by the National Natural Science Foundation of China, Top-Notch Young Talents in China Award by the Chinese Government, and Tang Scholar Award by the Tang International Foundation.

Selected Publications

1. Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, Fang Y, Wang Y, Liu J, Chi H, Sun Y, Ye R, Shan L, Shi J, Shen Z, Wang Y, Wang S, Brosseau JP, Wang F, Liu G, Quan Y, Xu J*, ITPRIPL1 binds CD3ε to impede T-cell activation and enable tumor immune evasion. Cell, 2024 Apr 5:S0092-8674(24)00310-6

2. Wang Y, Sun Y, Deng S, Liu J, Yu J, Chi H, Han X, Zhang Y, Shi J, Wang Y, Quan Y, Li H, Xu J*,Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. Cell Reports Medicine, 2024,5(1):101374 

3. Li C, Chi H, Deng S, Xu K, Wang H, Yao H, Wang Y, Chen D, Guo X, Fang JY, He F, Xu J^(*). THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. J Immunother Cancer. 2021 Aug;9(8):e002443.

4. Chushu Li, Han Yao, Huanbin Wang, Jing-Yuan Fang, Jie Xu^(*), Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity. Oncogene. 2020. DOI: 10.1038/s41388-020-01592-6

5. Jie Xu ^(*), Jean-Philippe Brosseau, and Hubing Shi, Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy. Oncogene. 2020; DOI: 10.1038/s41388-020-01491-w

6. Xu, J ^(*). (2020). Regulation of Cancer Immune Checkpoints. Springer Nature. Hardcover ISBN: 9811532656. Pages 1-653. (*Book Editor)

7. Wang, Huanbin^(#); Yao, Han; Li, Chushu; Shi, Hubing; Lan, Jiang; Li, Zhaoli; Zhang, Yao; Liang, Lunxi; Fang, Jing-Yuan; Xu, Jie^(*), HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nature Chemical Biology, 2019 (1): 42~50. (highly cited)

8. Han Yao; Jiang Lan; Chushu Li; Hubing Shi; Jean-Philippe Brosseau; Huanbin Wang; Haojie Lu; Caiyun Fang; Yao Zhang; Lunxi Liang; Xiaolin Zhou; Chaojun Wang; Yu Xue; Yun Cui; Jie Xu ^(*), Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours, Nature Biomedical Engineering, 2019; 3(5):414. (highly cited)

9. Liang L(#), Wang H(#), Shi H, Li Z, Yao H, Bu Z, Song N, Li C, Xiang D, Zhang Y, Wang J, Hu Y, Xu Q, Ma Y, Cheng Z, Wang Y, Zhao S, Qian J, Chen Y, Fang JY, Xu, J ^(*), A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity, Cell Chemical Biology, 2018, 25(6): 761~774

10. Qian J, Li Y, Yao H, Tian H, Wang H, Ai L, Xie Y, Bao Y, Liang L, Hu Y, Zhang Y, Wang J, Li C, Tang J, Chen Y, Xu, J ^(*), Fang JY^(*). ASAP3 regulates microvilli structure in parietal cells and presents intervention target for gastric acidity. Signal Transduction & Targeted Therapy. 2017; 2:17003

11. Wang, Huanbin^(#); Yao, Han^(#); Li, Chushu; Liang, Lunxi; Zhang, Yao; Shi, Hubing; Zhou, Chongzhi; Chen, Yingxuan; Fang, Jing-Yuan; Xu, Jie ^(*), PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation, Oncoimmunology, 2017, 6(7): e1327494

12. Zhang, Y.^(#); Hu, Y.^(#); Wang, J-L; Yao, H.; Wang, H.; Liang, L.; Li, C.; Shi, H.; Chen, Y.; Fang, J-Y; Xu, J.^(*), Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp, Oncogene, 2017, 36(39): 5473~5483

13. Yao, Han^(#); Wang, Huanbin; Li, Chushu; Fang, Jing-Yuan; Xu, Jie; Xu, J ^(*), Cancer Cell-intrinsic PD-1 and implications in Combinatorial immunotherapy, Frontiers in Immunology, 2018, 9(1774): 0~1774. (highly cited)

14. Xie, Yuan-Hong^(#); Gao, Qin-Yan; Zou, Tian-Hui; Chen, Hui-Min; Yu, Si-Yi; Qiu, Yi-Wen; Gu, Wei-Qi; Chen, Xiao-Yu; Cui, Yun; Sun, Danfeng; Xu, Jie; Chen, Ying-Xuan; Fang, Jing-Yuan; Cai, Guo-Xiang; Cai, San-Jun; Sun, Xiao-Ming; Liu, Zhan-Ju; Cai, SJ^(*); Xu, J ^(*); Chen, YX^(*); Fang, JY^(*), Fecal Clostridium symbiosum for Noninvasive Detection of Early and Advanced Colorectal Cancer: Test and Validation Studies, EBioMedicine, 2017, 25: 32~40

15. Wang H^(#); Liang L; Fang JY; Xu J ^(*), Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers, Oncogene, 2016, 35(304): 2011~2019. (highly cited)

16. Liang L^(#); Fang JY^(*); Xu J ^(*), Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy, Oncogene, 2016, 35(12): 1475~1482. (highly cited)

17. Qian, Jin^(#); Kong, Xuan^(#); Deng, Niantao; Tan, Patrick; Chen, Haoyan; Wang, Jilin; Li, Zhaoli; Hu, Ye; Zou, Weiping; Xu, Jie ^(*); Fang, Jing-Yuan^(*), OCT1 is a determinant of synbindin-related ERK signalling with independent prognostic significance in gastric cancer, Gut, 2015, 64(1): 37~48  

18. Wang, Jilin^(#); Qian, Jin^(#); Hu, Ye; Kong, Xuan; Chen, Haoyan; Shi, Qinghua; Jiang, Long; Wu, Chenming; Zou, Weiping; Chen, Yingxuan; Xu, Jie ^(*); Fang, Jing-Yuan^(*), ArhGAP30 promotes p53 acetylation and function in colorectal cancer, Nature Communications, 2014, 5: 5735

19. Hu, Ye^(#); Wang, Jilin; Qian, Jin; Kong, Xuan; Tang, Jieting; Wang, Yingchao; Chen, Haoyan; Hong, Jie; Zou, Weiping; Chen, Yingxuan; Xu, Jie ^(*); Fang, Jing-Yuan^(*), Long Noncoding RNA GAPLINC Regulates CD44-Dependent Cell Invasiveness and Associates with Poor Prognosis of Gastric Cancer, Cancer Research, 2014, 74(23): 6890~6902. (highly cited)

20. Xuan Kong, Jin Qian, Li-Sha Chen, Ying-Chao Wang, Ji-Lin Wang, Haoyan Chen, Yu-Rong Weng, Shu-Liang Zhao, Jie Hong, Ying-Xuan Chen, Weiping Zou, Jie Xu ^(*), Jing-Yuan Fang^(*), Synbindin in Extracellular Signal-Regulated Protein Kinase Spatial Regulation and Gastric Cancer Aggressiveness, JNCI:Journal of the National Cancer Institute, 2013, 105(22):1738-49